Aspirin Intolerance in the Setting of Acute Coronary Syndrome: Case Report and Review of Literature

Journal of Clinical Medicine of Kazakhstan, 2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.23950/jcmk/16252
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Acute coronary syndrome (ACS) requires prompt intervention to prevent myocardial ischemia. This case report describes a patient’s clinical journey, highlighting the challenges associated with aspirin intolerance and the necessity of an alternative antithrombotic approach. The patient, who presented with ACS and a documented history of aspirin-induced asthma and angioedema, was unable to undergo standard dual antiplatelet therapy (DAPT) with aspirin. Given the urgency of intervention and failed prior aspirin desensitization, ticagrelor and rivaroxaban were selected as alternative agents. The patient underwent successful percutaneous coronary intervention (PCI) with stent placement and was managed postoperatively using a modified antithrombotic regimen. The case underscores the importance of individualized therapy in aspirin-intolerant ACS patients and suggests a viable alternative strategy for anticoagulation and platelet inhibition. Patient outcomes were favorable, demonstrating effective ischemic risk mitigation without aspirin-related hypersensitivity reactions.